FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Antonio Craxì

Research Profile

Disorders

Living Beings

Chemicals & Drugs

Co-author Network

Publications

TOP 3
S Petta; Daniela Cabibi; Calogero Cammà; Vito Di Marco; A Handberg; F S Macaluso; G Marchesini; Antonio Craxì
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C.
Calogero Cammà; Massimo Colombo; Antonio Craxì; Marco Enea; Antonio Gasbarrini; Antonio Grieco; Massimo Iavarone; Salvatore Petta; Erica Villa; Claudio Zavaglia; Raffaele Bruno; Giuseppe Cabibbo
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
Salvatore Petta; Mario Rizzetto; Chiara Rosso; Federico Salomone; Antonina Smedile; Calogero Cammà; Paolo Caviglia; Antonio Craxì; Roberto Gambino; Jacob George; Stefania Grimaudo; Reynold Leung; Maria Lorena Abate; David Booth; Elisabetta Bugianesi
Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Antonio Craxì (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: S Petta; Daniela Cabibi; Calogero Cammà; Vito Di Marco; A Handberg; F S Macaluso; G Marchesini; Antonio Craxì
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C.
Journal of viral hepatitis 2013;20(3):174-82.
2013: Calogero Cammà; Massimo Colombo; Antonio Craxì; Marco Enea; Antonio Gasbarrini; Antonio Grieco; Massimo Iavarone; Salvatore Petta; Erica Villa; Claudio Zavaglia; Raffaele Bruno; Giuseppe Cabibbo
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
Hepatology (Baltimore, Md.) 2013;57(3):1046-54.
2013: Salvatore Petta; Mario Rizzetto; Chiara Rosso; Federico Salomone; Antonina Smedile; Calogero Cammà; Paolo Caviglia; Antonio Craxì; Roberto Gambino; Jacob George; Stefania Grimaudo; Reynold Leung; Maria Lorena Abate; David Booth; Elisabetta Bugianesi
Effects of IL28B rs12979860 CC genotype on metabolic profile and sustained virologic response in patients with genotype 1 chronic hepatitis C.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2013;11(3):311-7.e1.
2013: Vito Di Marco; R Di Stefano; D Ferraro; Stefania Grimaudo; R M Pipitone; V Calvaruso; Antonio Craxì
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices.
Journal of viral hepatitis 2013;20(2):113-21.
2013: Salvatore Petta; Antonio Craxì
How to optimize HCV therapy in genotype 1 patients: predictors of response.
Liver international : official journal of the International Association for the Study of the Liver 2013;33 Suppl 1():23-9.
2013: Anna Licata; Fabio Salvatore Macaluso; Antonio Craxì
Herbal hepatotoxicity: a hidden epidemic.
Internal and emergency medicine 2013;8(1):13-22.
2013: Anna Rita Giardina; Francesco Ciccia; Antonio Craxì; Rosa Di Stefano; Angelo Ferrante; Donatella Ferraro; Giovanni Triolo
No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.
Clinical and experimental rheumatology 2013;31(1):25-30.
2013: Salvatore Petta; Antonio Craxì
Reply.
Hepatology (Baltimore, Md.) 2013;57(1):422.
2012: Donatella Ferraro; Maria Gussio; Salvatore Magliocco; Paola Pizzillo; Noemi Urone; Bruno Cacopardo; Antonio Craxì; Vito Di Marco; Rosa Di Stefano
Phylogenetic analysis of isolates from new cases of HBV infection in Southern Italy.
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2012;12(8):1591-6.
2012: Salvatore Petta; Daniela Cabibi; Calogero Cammà; Fabio S Macaluso; Vito D Marco; Antonio Craxì
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection.
Liver international : official journal of the International Association for the Study of the Liver 2012;32(9):1443-50.
2012: Giuseppe Cabibbo; Calogero Cammà; Antonio Craxì; Chiara Genco; Marcello Maida; Pietro Parisi; Marco Peralta; Michela Antonucci; Giuseppe Brancatelli; Vito Di Marco
Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study.
World journal of hepatology 2012;4(9):256-61.
2012: Calogero Cammà; Vincenza Capursi; Americo Cicchetti; Giorgio L Colombo; Antonio Craxì; Vito Di Marco; Marco Enea; Antonio Gasbarrini; Salvatore Petta; Fabrizio Bronte; Raffaele Bruno
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.
Hepatology (Baltimore, Md.) 2012;56(3):850-60.
2012: Annagiulia Gramenzi; Antonio Grieco; Antonino Picciotto; Maria Rendina; Domenico Romagno; Gabriella Verucchi; Fausto Ancarani; Pietro Andreone; Mauro Bernardi; Calogero Cammà; Maria Chiaramonte; Fabio Conti; Paolo Costa; Antonio Craxì; Caterina Furlan
Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2012;44(8):674-80.
2012: Anna Licata; Claudia Randazzo; Ada M Florena; Piero L Almasio; Andrea Arini; Giuseppe Butera; Maria Cappello; Antonio Craxì
Serology in adults with celiac disease: limited accuracy in patients with mild histological lesions.
Internal and emergency medicine 2012;7(4):337-42.
2012: S Petta; Antonio Craxì; Vito Di Marco; A Mazzola; C Bellia; Daniela Cabibi; Calogero Cammà; A Caruso; Marcello Ciaccio
Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C.
Journal of viral hepatitis 2012;19(7):465-72.
2012: Anna Licata; Sergio Peralta; Claudia Randazzo; Ada M Florena; Giuseppe Butera; Vincenza Calvaruso; Calogero Cammà; Maria Cappello; Antonio Craxì
Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea.
Journal of clinical gastroenterology 2012;46(6):504-8.
2012: Salvatore Petta; Rosaria Maria Pipitone; Vito Di Marco; Daniela Cabibi; Calogero Cammà; Stefania Grimaudo; Giusalba Licata; Antonio Craxì
IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease.
Journal of hepatology 2012;56(6):1356-62.
2012: Anna Licata; Ilaria Morreale; Claudia Randazzo; Giuseppe Butera; Natale D'Alessandro; Antonio Craxì
Fluoroquinolone-induced liver injury: three new cases and a review of the literature.
European journal of clinical pharmacology 2012;68(5):525-32.
2012: Vito Di Marco; Flavia Fiorenza; Calogera Gerardi; Stefania Grimaudo; Massimo Levrero; Maria Carmela Lo Pinto; Aurelio Maggio; Lorella Pitrolo; Maria Concetta Renda; Michele Rizzo; Zelia Borsellino; Fabrizio Bronte; Vincenza Calvaruso; Marcello Capra; Antonietta Di Cristina; Antonio Craxì
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.
Haematologica 2012;97(5):679-86.
2012: Salvatore Petta; Daniele Torres; Daniela Cabibi; Calogero Cammà; Vito Di Marco; Giovanni Fazio; Anna Licata; Giuseppe Licata; Giulio Marchesini; Alessandra Mazzola; Salvatore Novo; Gaspare Parrinello; Antonio Craxì
Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations.
Hepatology (Baltimore, Md.) 2012;55(5):1317-23.
2012: Salvatore Petta; Antonio Craxì
Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe?
Hepatology (Baltimore, Md.) 2012;55(4):1309; author reply 1309-10.
2012: Mario Arciello; Carlo Cammà; Antonio Craxì; Gino Iannucci; Giancarlo Labbadia; Valerio Leoni; Salvatore Petta; Clara Balsano
Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus-infected patients.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2012;44(3):245-50.
2012: Salvatore Petta; Vito Di Marco; Fabio Salvatore Macaluso; Maria Rosa Barcellona; Daniela Cabibi; Calogero Cammà; Antonio Craxì
Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases.
PloS one 2012;7(12):e51165.
2012: Salvatore Petta; Antonio Craxì
Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat?
BMC infectious diseases 2012;12 Suppl 2():S3.
2012: Salvatore Petta; Concetta Scazzone; Daniela Cabibi; Calogero Cammà; Antonietta Di Cristina; Vito Di Marco; Rosa Di Stefano; Donatella Ferraro; Stefania Grimaudo; Massimo Levrero; Alessandra Mazzola; Antonio Craxì
Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.
Antiviral therapy 2012;17(5):823-31.
2012: Claudio Tripodo; Daniela Cabibi; Mario P Colombo; Carla Guarnotta; Salvatore Petta; Rosaria Pipitone; Antonio Craxì
Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients.
Antiviral therapy 2012;17(1):111-8.
2011: S Petta; Vito Di Marco; Daniela Cabibi; Calogero Cammà; Antonio Craxì
Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease.
Alimentary pharmacology & therapeutics 2011;34(7):757-66.
2011: Giuseppina Campisi; Olga Di Fede; Vito Di Marco; Anna Musciotto; Antonio Craxì
Halitosis: could it be more than mere bad breath?
Internal and emergency medicine 2011;6(4):315-9.
2011: S Petta; Daniela Cabibi; Calogero Cammà; Vito Di Marco; R Di Stefano; G Marchesini; Antonio Craxì
TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.
Journal of viral hepatitis 2011;18(7):e372-80.
2011: Piero L Almasio; Antonio Craxì
Management of hepatitis B virus infection in the underprivileged world.
Liver international : official journal of the International Association for the Study of the Liver 2011;31(6):749-50.
2011: Giovanni Raimondo; Massimo Levrero; Teresa Pollicino; Antonio Craxì
Occult hepatitis B virus infection and hepatocellular carcinoma development in patients with chronic hepatitis C.
Hepatology (Baltimore, Md.) 2011;54(1):373-4; author reply 374.
2011: Vito Di Marco; Alessandra Iacò; Katiela Prestini; Massimo Puoti; Paolo Sacchi; Giovanni Squadrito; Giuliana Amaddeo; Luciano Biasi; Fabrizio Bronte; Raffaele Bruno; Vincenza Calvaruso; Antonio Craxì
Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis.
Gut 2011;60(7):1023.
2011: S Petta; Vito Di Marco; Calogero Cammà; G Butera; Daniela Cabibi; Antonio Craxì
Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index.
Alimentary pharmacology & therapeutics 2011;33(12):1350-60.
2011: Salvatore Petta; Claudio Tripodo; Stefania Grimaudo; Daniela Cabibi; Calogero Cammà; Antonietta Di Cristina; Vito Di Marco; Gaetano Di Vita; Sabrina Ingrao; Alessandra Mazzola; Giulio Marchesini; Rosaria Pipitone; Antonio Craxì
High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2011;43(5):404-10.
2011: Vincenza Calvaruso; Antonio Craxì
Fibrosis in chronic viral hepatitis.
Best practice & research. Clinical gastroenterology 2011;25(2):219-30.
2011: Salvatore Petta; Calogero Cammà; Vito Di Marco; Fabio Salvatore Macaluso; Marcello Maida; Giuseppe Pizzolanti; Beatrice Belmonte; Daniela Cabibi; Rosa Di Stefano; Donatella Ferraro; Carla Guarnotta; Giovanna Venezia; Antonio Craxì
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection.
Liver international : official journal of the International Association for the Study of the Liver 2011;31(4):507-15.
2011: Giampiero Carosi; Mario Rizzetto; Alfredo Alberti; Giuseppe Cariti; Massimo Colombo; Antonio Craxì; Gaetano Filice; Massimo Levrero; Francesco Mazzotta; Giuseppe Pastore; Felice Piccinino; Daniele Prati; Giovanni Raimondo; evangelista sagnelli; Mario Toti; Maurizia Brunetto; Raffaele Bruno; Vito Di Marco; Carlo Ferrari; Giovanni B Gaeta; Pietro Lampertico; Alfredo Marzano; Teresa Pollicino; Massimo Puoti; Teresa Santantonio; Antonina Smedile
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2011;43(4):259-65.
2011: Maria Cappello; Stefania Grimaudo; Ivana Bravatá; Claudia Randazzo; Rosaria Maria Pipitone; Anna Licata; Calogero Cammá; Antonio Craxì
Genetic predisposition to thrombophilia in inflammatory bowel disease.
Journal of clinical gastroenterology 2011;45(3):e25-9.
2011: Salvatore Petta; Antonio Craxì
Optimal therapy in hepatitis C virus genotypes 2 and 3 patients.
Liver international : official journal of the International Association for the Study of the Liver 2011;31 Suppl 1():36-44.
2011: Stefania De Lisi; Sergio Peralta; Andrea Arini; Fabio Simone; Antonio Craxì
Oesophagogastroduodenoscopy in patients with cirrhosis: Extending the range of detection beyond portal hypertension.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2011;43(1):48-53.
2010: Francesco Ciccia; Antonina Accardo-Palumbo; Anna Giardina; Piera Di Maggio; Alfonso Principato; Michele Bombardieri; Aroldo Rizzo; Riccardo Alessandro; Angelo Ferrante; Simona Principe; Sergio Peralta; Francesco Conte; Sandro Drago; Antonio Craxì; Giacomo De Leo; Giovanni Triolo
Expansion of intestinal CD4+CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response.
Arthritis and rheumatism 2010;62(12):3625-34.
2010: Salvatore Petta; Marco Amato; Daniela Cabibi; Calogero Cammà; Vito Di Marco; Carla Giordano; Aldo Galluzzo; Antonio Craxì
Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1.
Hepatology (Baltimore, Md.) 2010;52(5):1543-52.
2010: Vito Di Marco; Marcello Capra; Emanuele Angelucci; Caterina Borgna-Pignatti; Paul Telfer; Paul Harmatz; Antonis Kattamis; Luciano Prossamariti; Aldo Filosa; Deborah Rund; Maria Rita Gamberini; Paolo Cianciulli; Marianne De Montalembert; Francesco Gagliardotto; Graham Foster; Jean Didier Grangè; Filippo Cassarà; Angela Iacono; Maria Domenica Cappellini; Gary Brittenham; Daniele Prati; Antonello Pietrangelo; Antonio Craxì; Aurelio Maggio
Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel.
Blood 2010;116(16):2875-83.
2010: Daniela Cabibi; Giuseppe Tarantino; Franco Barbaria; Maria Campione; Antonio Craxì; Vito Di Marco
Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42(8):585-92.
2010: Antonio Craxì; Calogero Cammà
Does chemotherapy prevent HCV-related hepatocellular carcinoma? Cons.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42 Suppl 3():S287-92.
2010: V Calvaruso; C Cammà; V Di Marco; S Maimone; F Bronte; M Enea; V Dardanoni; P Manousou; M Pleguezuelo; E Xirouchakis; M Attanasio; G Dusheiko; A K Burroughs; Antonio Craxì
Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy.
Journal of viral hepatitis 2010;17(7):469-74.
2010: G Cabibbo; Antonio Craxì
Epidemiology, risk factors and surveillance of hepatocellular carcinoma.
European review for medical and pharmacological sciences 2010;14(4):352-5.
2010: Giuseppe Cabibbo; Marco Enea; Massimo Attanasio; Jordi Bruix; Antonio Craxì; Calogero Cammà
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma.
Hepatology (Baltimore, Md.) 2010;51(4):1274-83.
2010: Vito Di Marco; Fabrizio Bronte; Daniela Cabibi; Vincenza Calvaruso; Giuseppe Alaimo; Zelia Borsellino; Francesco Gagliardotto; Piero Luigi Almasio; Marcello Capra; Antonio Craxì
Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition.
British journal of haematology 2010;148(3):476-9.
2010: Anna Licata; V Calvaruso; M Cappello; Antonio Craxì; Piero Luigi Almasio
Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2010;42(2):143-8.
2010: S Petta; Antonio Craxì
Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association.
Current pharmaceutical design 2010;16(6):741-52.
2010: Antonio Craxì
PEG IFN alfa-2a vs. alfa-2b: and the winner is ...?
Journal of hepatology 2010;52(1):133-5.
2009: Giuseppe Cabibbo; Antonio Craxì
Needle track seeding following percutaneous procedures for hepatocellular carcinoma.
World journal of hepatology 2009;1(1):62-6.
2009: Calogero Cammà; Giuseppe Cabibbo; Fabrizio Bronte; Marco Enea; Anna Licata; Massimo Attanasio; Angelo Andriulli; Antonio Craxì
Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis.
Journal of hepatology 2009;51(4):675-81.
2009: S Petta; Calogero Cammà; Vito Di Marco; V Calvaruso; M Enea; F Bronte; G Butera; Daniela Cabibi; Antonio Craxì
Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis.
Alimentary pharmacology & therapeutics 2009;30(6):603-13.
2009: Donatella Ferraro; Paola Pizzillo; Vito Di Marco; Anna Vultaggio; Emilio Iannitto; Giovanna Venezia; Antonio Craxì; Rosa Di Stefano
Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?
Liver international : official journal of the International Association for the Study of the Liver 2009;29(8):1171-7.
2009: S Petta; C Muratore; Antonio Craxì
Non-alcoholic fatty liver disease pathogenesis: the present and the future.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2009;41(9):615-25.
2009: Vincenza Calvaruso; Antonio Craxì
Implication of normal liver enzymes in liver disease.
Journal of viral hepatitis 2009;16(8):529-36.
2009: Giuseppe Licata; Antonino Tuttolomondo; Anna Licata; G Parrinello; Domenico Di Raimondo; R Di Sciacca; Calogero Cammà; Antonio Craxì; S Paterna; Antonio Pinto
Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites.
Alimentary pharmacology & therapeutics 2009;30(3):227-35.
2009: Paola Pizzillo; Piero Luigi Almasio; Donatella Ferraro; Antonio Craxì; Rosa Di Stefano
HCV genotypes in Sicily: is there any evidence of a shift?
Journal of medical virology 2009;81(6):1040-6.
2009: G Tarantino; V D Marco; S Petta; Piero Luigi Almasio; Franco Barbaria; Anna Licata; G L Bosco; C Tripodo; Rosalba Stefano; Antonio Craxì
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection.
Journal of viral hepatitis 2009;16(6):397-405.
2009: Anna Licata; Maria Elena Nebbia; Giuseppe Cabibbo; Giuseppe Iacono; Franco Barbaria; Virna Brucato; Nicola Alessi; Salvatore Porrovecchio; Vito Di Marco; Antonio Craxì; Calogero Cammà
Hyperferritinemia is a risk factor for steatosis in chronic liver disease.
World journal of gastroenterology : WJG 2009;15(17):2132-8.
2009: Amedeo Lonardo; Luigi Elio Adinolfi; Salvatore Petta; Antonio Craxì; Paola Loria
Hepatitis C and diabetes: the inevitable coincidence?
Expert review of anti-infective therapy 2009;7(3):293-308.
2009: Vito Di Marco; Antonio Craxì
Chronic hepatitis B: who to treat and which choice of treatment?
Expert review of anti-infective therapy 2009;7(3):281-91.
2009: Giuseppe Cabibbo; Federica Latteri; Michela Antonucci; Antonio Craxì
Multimodal approaches to the treatment of hepatocellular carcinoma.
Nature clinical practice. Gastroenterology & hepatology 2009;6(3):159-69.
2009: Antonio Craxì
Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?
Antiviral therapy 2009;14(8):1045-9.
2009: Teresa Pollicino; Graziella Isgrò; Rosa Di Stefano; Donatella Ferraro; Sergio Maimone; Santa Brancatelli; Giovanni Squadrito; Vito Di Marco; Antonio Craxì; Giovanni Raimondo
Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
Antiviral therapy 2009;14(5):649-54.
2009: Salvatore Petta; Calogero Cammà; Vito Di Marco; Daniela Cabibi; Stefania Ciminnisi; Rosalia Caldarella; Anna Licata; MF Massenti; Giulio Marchesini; Antonio Craxì
Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
Antiviral therapy 2009;14(5):631-9.
2009: Giuseppe Cabibbo; Antonio Craxì
Hepatocellular cancer: optimal strategies for screening and surveillance.
Digestive diseases (Basel, Switzerland) 2009;27(2):142-7.
2009: Giuseppe Tarantino; Antonio Craxì
Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review.
Liver international : official journal of the International Association for the Study of the Liver 2009;29 Suppl 1():31-8.
2009: Calogero Cammà; Salvatore Petta; Vito Di Marco; Fabrizio Bronte; Stefania Ciminnisi; Giusalba Licata; Sergio Peralta; Fabio Simone; Giulio Marchesini; Antonio Craxì
Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis.
Hepatology (Baltimore, Md.) 2009;49(1):195-203.
2009: Giuseppina Campisi; Domenico Compilato; Giuseppe Iacono; E Maresi; Chiara Di Liberto; Vito Di Marco; Gaetana Di Fede; Antonio Craxì; Antonio Carroccio
Histomorphology of healthy oral mucosa in untreated celiac patients: unexpected association with spongiosis.
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2009;38(1):34-41.
2008: Giovanni Raimondo; Jean-Pierre Allain; Maurizia R Brunetto; Marie Annick Buendia; Ding-Shinn Chen; Massimo Colombo; Antonio Craxì; Francesco Donato; Carlo Ferrari; Giovanni B Gaeta; Wolfram H Gerlich; Massimo Levrero; Stephen Locarnini; Thomas Michalak; Mario U Mondelli; Jean-Michel Pawlotsky; Teresa Pollicino; Daniele Prati; Massimo Puoti; Didier Samuel; Daniel Shouval; Antonina Smedile; Giovanni Squadrito; Christian Trépo; Erica Villa; Hans Will; Alessandro R Zanetti; Fabien Zoulim
Statements from the Taormina expert meeting on occult hepatitis B virus infection.
Journal of hepatology 2008;49(4):652-7.
2008: Donatella Ferraro; Genovese Domenico; Claudio Argentini; Viviana Giordano; Paola Pizzillo; Tommaso Stroffolini; Antonio Craxì; Maria Rapicetta; Rosa Di Stefano
Phylogenetic reconstruction of HCV genotype 1b dissemination in a small city centre: the Camporeale model.
Journal of medical virology 2008;80(10):1723-31.
2008: Rosalia Patti; Piero Luigi Almasio; Salvatore Buscemi; Fausto Famà; Antonio Craxì; Gaetano Di Vita
Inguinal hernioplasty improves the quality of life in patients with cirrhosis.
American journal of surgery 2008;196(3):373-8.
2008: Anna Linda Zignego; Antonio Craxì
Extrahepatic manifestations of hepatitis C virus infection.
Clinics in liver disease 2008;12(3):611-36, ix.
2008: Vito Di Marco; Marcello Capra; Francesco Gagliardotto; Zelia Borsellino; Daniela Cabibi; Franco Barbaria; Donatella Ferraro; Liana Cuccia; Giovanni Battista Ruffo; Fabrizio Bronte; Rosa Di Stefano; Piero Luigi Almasio; Antonio Craxì
Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.
Haematologica 2008;93(8):1243-6.
2008: Federica Latteri; Luigi Sandonato; Vito Di Marco; Piero Parisi; Giuseppe Cabibbo; G Lombardo; Massimo Galia; Massimo Midiri; Mario Adelfio Latteri; Antonio Craxì
Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2008;40(8):684-9.
2008: Salvatore Petta; Calogero Cammà; Vito Di Marco; Nicola Alessi; Francesco Barbaria; Daniela Cabibi; Rosalia Caldarella; Stefania Ciminnisi; Anna Licata; MF Massenti; Alessandra Mazzola; Giuseppe Tarantino; Giulio Marchesini; Antonio Craxì
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1.
Hepatology (Baltimore, Md.) 2008;48(1):28-37.
2008: Calogero Cammà; Vito Di Marco; Giuseppe Cabibbo; Federica Latteri; Luigi Sandonato; Piero Parisi; M Enea; M Attanasio; Massimo Galia; N Alessi; Anna Licata; Mario Adelfio Latteri; Antonio Craxì
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems.
Alimentary pharmacology & therapeutics 2008;28(1):62-75.
2008: G Tarantino; Daniela Cabibi; Calogero Cammà; N Alessi; Maria Donatelli; S Petta; Antonio Craxì; Vito Di Marco
Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C.
Journal of viral hepatitis 2008;15(7):523-30.
2008: Salvatore Petta; Calogero Cammà; Vito Di Marco; Nicola Alessi; Daniela Cabibi; Rosalia Caldarella; Anna Licata; Fatima Massenti; Giuseppe Tarantino; Giulio Marchesini; Antonio Craxì
Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection.
The American journal of gastroenterology 2008;103(5):1136-44.
2008: Antonio Craxì; Giacomo Laffi; Anna Linda Zignego
Hepatitis C virus (HCV) infection: a systemic disease.
Molecular aspects of medicine 2008;29(1-2):85-95.
2008: Donatella Ferraro; Maria Giglio; Celestino Bonura; Vito Di Marco; Mario U Mondelli; Antonio Craxì; Rosa Di Stefano
Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay.
Journal of viral hepatitis 2008;15(1):66-70.
2007: Giuseppina Campisi; Chiara Di Liberto; Giuseppe Iacono; Domenico Compilato; Lidia Di Prima; Francesco Calvino; Vito Di Marco; Lorenzo Lo Muzio; Carmela Sferrazza; Calogero Scalici; Antonio Craxì; Antonio Carroccio
Oral pathology in untreated coeliac [corrected] disease.
Alimentary pharmacology & therapeutics 2007;26(11-12):1529-36.
2007: Antonio Craxì
Introduction. Necroinflammation and the course of chronic hepatitis.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2007;39 Suppl 3():S369-71.
2007: Vito Di Marco; Antonio Craxì
Adefovir for lamivudine resistant HBV: more than meets the eye.
Journal of hepatology 2007;47(4):618-9; author reply 619-20.
2007: Patrick Marcellin; E Jenny Heathcote; Antonio Craxì
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?
Journal of hepatology 2007;47(4):580-7.
2007: Vito Di Marco; Piero Luigi Almasio; Donatella Ferraro; Vincenza Calvaruso; Giuseppe Alaimo; Sergio Peralta; Rosa Di Stefano; Antonio Craxì
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.
Journal of hepatology 2007;47(4):484-91.
2007: Antonio Carroccio; Giuseppina Campisi; Giuseppe Iacono; O Lo Iacono; Emiliano Maresi; Lidia Di Prima; Domenico Compilato; Franco Barbaria; A Arini; Chiara Di Liberto; Giuseppe Pirrone; Antonio Craxì; Vito Di Marco
Oral mucosa of coeliac disease patients produces antiendomysial and antitransglutaminase antibodies: the diagnostic usefulness of an in vitro culture system.
Alimentary pharmacology & therapeutics 2007;25(12):1471-7.
2006: Luigi Pagliaro; Bruno Gridelli; Antonio Craxì
[Hepatology: yesterday, today and (maybe) tomorrow].
Recenti progressi in medicina 2006;97(12):741-50.
2006: Giuseppe Alaimo; Vito Di Marco; Donatella Ferraro; Rosa Di Stefano; Salvatore Porrovecchio; Francesca D'Angelo; Vincenza Calvaruso; Antonio Craxì; Piero Luigi Almasio
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial.
World journal of gastroenterology : WJG 2006;12(42):6861-4.
2006: Nicasio Mancini; Silvia Carletti; Mario Perotti; Luisa Romano'; Rosellina Di Stefano Craxì; Antonio Craxì; Alessandro R Zanetti; Massimo Clementi; Roberto Burioni
Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
Journal of medical virology 2006;78(10):1304-11.
2006: Danilo Di Bona; Marco Cippitelli; Cinzia Fionda; Calogero Cammà; Anna Licata; Angela Santoni; Antonio Craxì
Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway.
Journal of hepatology 2006;45(2):271-9.
2006: Antonio Craxì; Cihan Yurdaydin
From viral pathobiology to the treatment of hepatitis B virus infection EASL Monothematic Conference (Istanbul, Turkey, October 6-8, 2005).
Journal of hepatology 2006;44(6):1186-95.
2006: Antonio Craxì; Anna Licata
Acute hepatitis C: in search of the optimal approach to cure.
Hepatology (Baltimore, Md.) 2006;43(2):221-4.
2006: Calogero Cammà; Savino Bruno; Vito Di Marco; Danilo Di Bona; Mariagrazia Rumi; Maria Vinci; Chiara Rebucci; Agostino Cividini; Giuseppe Pizzolanti; Ernesto Minola; Mario U Mondelli; Massimo Colombo; Giovanbattista Pinzello; Antonio Craxì
Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C.
Hepatology (Baltimore, Md.) 2006;43(1):64-71.
2006: Antonio Craxì; Giorgio Antonucci; Calogero Cammà
Treatment options in HBV.
Journal of hepatology 2006;44(1 Suppl):S77-83.
2006: Antonio Craxì; Calogero Cammà
Treating patients with HCV genotype 1 and low viraemia: more than meets the eye.
Journal of hepatology 2006;44(1):4-7.
2005: Oreste Lo Iacono; Salvatore Petta; Giovanna Venezia; Vito Di Marco; Giuseppe Tarantino; Franco Barbaria; Claudia Mineo; Stefania De Lisi; Piero Luigi Almasio; Antonio Craxì
Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease?
The American journal of gastroenterology 2005;100(11):2472-7.
2005: Giovanna Venezia; Anna Licata; Vito Di Marco; Antonio Craxì; Piero Luigi Almasio
Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2005;37(11):882-5.
2005: Peter Ferenci; Michael W Fried; Mitchell L Shiffman; Coleman I Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moisés Diago; Giampero Carosi; Daniel Dhumeaux; Antonio Craxì; Monique Chaneac; K Rajender Reddy
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.
Journal of hepatology 2005;43(3):425-33.
2005: Anna Licata; Vito Di Marco; Piero Parisi; Federica Latteri; M E Nebbia; Giuseppe Cabibbo; Danilo Di Bona; Gabriele Prinzi; Sergio Li Petri; Luigi Sandonato; Mario Adelfio Latteri; Antonio Craxì; Calogero Cammà
Radio-frequency thermal ablation (RFTA) of small hepatocellular carcinoma in patients with cirrhosis. Experience at a single tertiary referral center.
Minerva gastroenterologica e dietologica 2005;51(2):171-8.
2005: Antonio Craxì; Calogero Cammà
Prevention of hepatocellular carcinoma.
Clinics in liver disease 2005;9(2):329-46, viii.
2005: Calogero Cammà; Vito Di Marco; Ambrogio Orlando; Luigi Sandonato; Andrea Casaril; Piero Parisi; Silvia Alizzi; Elio Sciarrino; Roberto Virdone; Salvatore Pardo; Danilo Di Bona; Anna Licata; Federica Latteri; Giuseppe Cabibbo; Giuseppe Montalto; Mario Adelfio Latteri; Nicola Nicoli; Antonio Craxì
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study.
Journal of hepatology 2005;42(4):535-40.
2005: Calogero Cammà; Anna Licata; Giuseppe Cabibbo; Federica Latteri; Antonio Craxì
Treatment of hepatitis C: critical appraisal of the evidence.
Expert opinion on pharmacotherapy 2005;6(3):399-408.
2005: Vito Di Marco; Rosa Di Stefano; Donatella Ferraro; Piero Luigi Almasio; Celestino Bonura; Maria Giglio; Piero Parisi; Maria Cappello; Giuseppe Alaimo; Antonio Craxì
HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.
Antiviral therapy 2005;10(3):431-9.
2004: Tommaso Stroffolini; evangelista sagnelli; Alfonso Mele; Antonio Craxì; Piero Luigi Almasio
The aetiology of chronic hepatitis in Italy: results from a multicentre national study.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2004;36(12):829-33.
2004: Antonio Craxì
Early virologic response with pegylated interferons.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2004;36 Suppl 3():S340-3.
2004: Vito Di Marco; Angelo V Marzano; Pietro Lampertico; Pietro Andreone; Teresa Santantonio; Piero Luigi Almasio; Mario Rizzetto; Antonio Craxì
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.
Hepatology (Baltimore, Md.) 2004;40(4):883-91.
2004: Giuseppina Campisi; Stefano Fedele; Lucio Lo Russo; Olga Di Fede; Pietro Aricò; Antonio Craxì; M D Mignogna
HCV infection and oral lichen planus: a weak association when HCV is endemic.
Journal of viral hepatitis 2004;11(5):465-70.
2004: Savino Bruno; Calogero Cammà; Vito Di Marco; Mariagrazia Rumi; Maria Vinci; Mario Camozzi; Chiara Rebucci; Danilo Di Bona; Massimo Colombo; Antonio Craxì; Mario U Mondelli; Giovanbattista Pinzello
Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial.
Journal of hepatology 2004;41(3):474-81.
2004: Anna Licata; Virna Brucato; Vito Di Marco; Franco Barbaria; Antonio Craxì
[Iron overload disease: recent findings].
Annali italiani di medicina interna : organo ufficiale della Società italiana di medicina interna 2004;19(3):145-54.
2004: fiorica francesco; Danilo Di Bona; Filippo Schepis; A Licata; Lillian Shahied; A Venturi; Anna Maria Falchi; Antonio Craxì; Calogero Cammà
Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis.
Gut 2004;53(7):925-30.
2004: Anna Licata; Filippo Barbiera; Giovanna Venezia; Giuseppe Runza; Antonio Craxì; P L Almasio
A woman with a long history of abdominal pain.
Minerva gastroenterologica e dietologica 2004;50(2):183-5.
2004: T Stroffolini; Guido Colloredo; Giovanni B Gaeta; Aurelio Sonzogni; Stefano Angeletti; Massimo Marignani; Giuseppe Pasquale; Giovanna Venezia; Antonio Craxì; Piero Luigi Almasio
Does an 'autoimmune' profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey.
Journal of viral hepatitis 2004;11(3):257-62.
2004: Isabella Abbate; Oreste Lo Iacono; Rosa Di Stefano; Giuseppina Cappiello; Enrico Girardi; Roberta Longo; Donatella Ferraro; Giorgio Antonucci; Vito Di Marco; Mariacarmela Solmone; Antonio Craxì; Giuseppe Ippolito; Maria Rosaria Capobianchi
HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin.
Journal of hepatology 2004;40(5):831-6.
2004: Calogero Cammà; Danilo Di Bona; Filippo Schepis; E Jenny Heathcote; Stefan Zeuzem; Paul J Pockros; Patrick Marcellin; Luis Balart; Alfredo Alberti; Antonio Craxì
Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data.
Hepatology (Baltimore, Md.) 2004;39(2):333-42.
2004: Calogero Cammà; Danilo Di Bona; Antonio Craxì
The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach.
Current pharmaceutical design 2004;10(17):2123-30.
2004: Anna Licata; Antonio Craxì
Interferon therapy: the other face of the medal.
Annali italiani di medicina interna : organo ufficiale della Società italiana di medicina interna 2004;19(1):5-7.
2004: Tommaso Stroffolini; evangelista sagnelli; Piero Luigi Almasio; Luigina Ferrigno; Antonio Craxì; Alfonso Mele
Characteristics of liver cirrhosis in Italy: results from a multicenter national study.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2004;36(1):56-60.
2003: Piero Luigi Almasio; Giovanna Venezia; Antonio Craxì
The impact of antiviral therapy on the course of chronic HCV infection. A systematic review.
Panminerva medica 2003;45(3):175-82.
2003: Domenico Lio; Calogero Caruso; Rosa Di Stefano; Giuseppina Colonna-Romano; Donatella Ferraro; Letizia Scola; Antonio Crivello; Anna Licata; Lilli Mario Valenza; Giuseppina Candore; Antonio Craxì; Piero Luigi Almasio
IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection.
Human immunology 2003;64(7):674-80.
2003: Donatella Ferraro; Celestino Bonura; Maria Giglio; Rosa Di Stefano; Piero Luigi Almasio; Vito Di Marco; Antonio Craxì; Irene Cacciola; Giovanni Squadrito; Giovanni Raimondo
Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
Journal of biological regulators and homeostatic agents 2003;17(2):172-5.
2003: Isabella Abbate; Giuseppina Cappiello; Oreste Lo Iacono; Roberta Longo; Donatella Ferraro; Giorgio Antonucci; Vito Di Marco; Rosa Di Stefano; Antonio Craxì; Mariacarmela Solmone; Alberto Spanò; Giuseppe Ippolito; Maria Rosaria Capobianchi
Heterogeneity of HVR-1 quasispecies is predictive of early but not sustained virological response in genotype 1b-infected patients undergoing combined treatment with PEG- or STD-IFN plus RBV.
Journal of biological regulators and homeostatic agents 2003;17(2):162-5.
2003: Roberta Nardacci; Oreste Lo Iacono; Fabiola Ciccosanti; Laura Falasca; Maria Addesso; Alessandra Amendola; Giorgio Antonucci; Antonio Craxì; Gian Maria Fimia; Valentina Iadevaia; Gerry Melino; Luigi Ruco; Guido Tocci; Giuseppe Ippolito; Mauro Piacentini
Transglutaminase type II plays a protective role in hepatic injury.
The American journal of pathology 2003;162(4):1293-303.
2003: Serenella Arista; Simona De Grazia; Vito Di Marco; Rosa Di Stefano; Antonio Craxì
Parvovirus B19 and "cryptogenic" chronic hepatitis.
Journal of hepatology 2003;38(3):375-6.
2003: Antonio Craxì; Danilo Di Bona; Calogero Cammà
Interferon-alpha for HBeAg-positive chronic hepatitis B.
Journal of hepatology 2003;39 Suppl 1():S99-105.
2003: Daniela Cabibi; Anna Licata; Elisabetta Barresi; Antonio Craxì; Francesco Aragona
Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract.
Pathology, research and practice 2003;199(2):65-70.
2002: Calogero Cammà; Savino Bruno; Filippo Schepis; Oreste Lo Iacono; Pietro Andreone; Annagiulia Gramenzi; alessandra mangia; Angelo Andriulli; M Puoti; A Spadaro; Maria Antonietta Freni; Vito Di Marco; L Cino; G Saracco; A Chiesa; Andrea Crosignani; N Caporaso; Filomena Morisco; Mariagrazia Rumi; Antonio Craxì
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data.
Gut 2002;51(6):864-9.
2002: Vito Di Marco; Donatella Ferraro; Piero Luigi Almasio; A Vaccaro; Piero Parisi; M Cappello; N Cino; Rosa Di Stefano; Antonio Craxì
Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction.
Journal of viral hepatitis 2002;9(5):354-9.
2002: Alfredo Alberti; Maurizia Rossana Brunetto; Massimo Colombo; Antonio Craxì
Recent progress and new trends in the treatment of hepatitis B.
Journal of medical virology 2002;67(3):458-62.
2002: Rosa Di Stefano; Tommaso Stroffolini; Donatella Ferraro; Antonella Usticano; Lilli Mario Valenza; Luigi Montalbano; Giuseppina Pomara; Antonio Craxì
Endemic hepatitis C virus infection in a Sicilian town: further evidence for iatrogenic transmission.
Journal of medical virology 2002;67(3):339-44.
2002: Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.
Radiology 2002;224(1):47-54.
2002: Giovanni Squadrito; Maria Elena Orlando; Teresa Pollicino; Giuseppina Raffa; Tea Restuccia; Irene Cacciola; Vito Di Marco; Antonino Picciotto; Giuseppe Colucci; Antonio Craxì; Giovanni Raimondo
Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection.
The American journal of gastroenterology 2002;97(6):1518-23.
2002: Calogero Cammà; fiorica francesco; Antonio Craxì; Mario Cottone
Preoperative and postoperative radiotherapy and survival in colorectal cancer.
Lancet 2002;359(9311):1068; author reply 1069.
2002: Stefano R Di; Donatella Ferraro; Celestino Bonura; Pizzolanti G Lo; O Lacono; Vito Di Marco; Antonio Craxì
Are hepatitis G virus and TT virus involved in cryptogenic chronic liver disease?
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2002;34(1):53-8.
2001: Vito Di Marco; A Vaccaro; Donatella Ferraro; Giuseppe Alaimo; Vito Rodolico; Piero Parisi; S Peralta; Rosa Di Stefano; Piero Luigi Almasio; Antonio Craxì
High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C.
Alimentary pharmacology & therapeutics 2001;15(7):953-8.
2001: Annagiulia Gramenzi; Pietro Andreone; S Fiorino; Calogero Cammà; M Giunta; Donatella Magalotti; Carmela Cursaro; Carlo Calabrese; V Arienti; C Rossi; Giulio Di Febo; Marco Zoli; Antonio Craxì; Giovanni Gasbarrini; Mauro Bernardi
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.
Gut 2001;48(6):843-8.
2001: Calogero Cammà; M Giunta; Pietro Andreone; Antonio Craxì
Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.
Journal of hepatology 2001;34(4):593-602.
2001: Filippo Schepis; Calogero Cammà; D Niceforo; A Magnano; S Pallio; Maurizio Cinquegrani; G D'amico; L Pasta; Antonio Craxì; Antonino Saitta; Giovanni Raimondo
Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection?
Hepatology (Baltimore, Md.) 2001;33(2):333-8.
2000: Giovanni Raimondo; Clara Balsano; Antonio Craxì; Fabio Farinati; Massimo Levrero; M Mondelli; Teresa Pollicino; Giovanni Squadrito; C Tiribelli
Occult hepatitis B virus infection.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2000;32(9):822-6.
2000: Piero Luigi Almasio; A Floreani; M Chiaramonte; Giuseppa Provenzano; Pier Maria Battezzati; Andrea Crosignani; M Podda; luca todros; Floriano Rosina; Gioconda Saccoccio; Federico Manenti; G Ballardini; F P Bianchi; P J Scheuer; S E Davies; Antonio Craxì
Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis.
Alimentary pharmacology & therapeutics 2000;14(12):1645-52.
2000: Tullio Prestileo; G Mazzola; Francesco Di Lorenzo; P Colletti; Francesco Vitale; Donatella Ferraro; Rosa Di Stefano; Calogero Cammà; Antonio Craxì
Response-adjusted alpha-interferon therapy for chronic hepatitis C in HIV-infected patients.
International journal of antimicrobial agents 2000;16(3):373-8.
2000: Vito Di Marco; Piero Luigi Almasio; A Vaccaro; Donatella Ferraro; Piero Parisi; MG Cataldo; Rosa Di Stefano; Antonio Craxì
Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.
Journal of hepatology 2000;33(3):456-62.
2000: Calogero Cammà; M Giunta; fiorica francesco; Luigi Pagliaro; Antonio Craxì; Mario Cottone
Preoperative radiotherapy for resectable rectal cancer: A meta-analysis.
JAMA : the journal of the American Medical Association 2000;284(8):1008-15.
2000: Antonio Craxì; Calogero Cammà; M Giunta
Clinical aspects of bleeding complications in cirrhotic patients.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2000;11 Suppl 1():S75-9.
1999: Calogero Cammà; M Giunta; L Chemello; A Alberti; H Toyoda; C Trepo; P Marcellin; F Zahm; S Schalm; Antonio Craxì
Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP).
Hepatology (Baltimore, Md.) 1999;30(3):801-7.
1999: Vito Di Marco; Oreste Lo Iacono; Calogero Cammà; A Vaccaro; M Giunta; G Martorana; P Fuschi; Piero Luigi Almasio; Antonio Craxì
The long-term course of chronic hepatitis B.
Hepatology (Baltimore, Md.) 1999;30(1):257-64.
1999: Tommaso Stroffolini; Pietro Andreone; Angelo Andriulli; Antonio Ascione; Antonio Craxì; Maria Chiaramonte; D Galante; Onofrio G Manghisi; Roberto Mazzanti; C Medaglia; G Pilleri; G L Rapaccini; M Albanese; Gloria Taliani; Maria Elena Tosti; Erica Villa; G Gasbarrini
Gross pathologic types of hepatocellular carcinoma in Italy.
Oncology 1999;56(3):189-92.
1998: Danilo Di Bona; Giuseppe Montalto; L Clemenza; F Bascone; P Accardo; Diana Bellavia; Antonio Craxì; Maria Brai
Soluble complement receptor type 1 (sCR1) in chronic liver diseases: serum levels at different stages of liver diseases.
Clinical and experimental immunology 1998;114(1):102-5.
1998: Calogero Cammà; Vito Di Marco; Oreste Lo Iacono; Piero Luigi Almasio; M Giunta; P Fuschi; A Vaccaro; Carmelo Fabiano; S Magrin; Rosa Di Stefano; Celestino Bonura; Luigi Pagliaro; Antonio Craxì
Long-term course of interferon-treated chronic hepatitis C.
Journal of hepatology 1998;28(4):531-7.
1997: Vito Di Marco; Oreste Lo Iacono; Piero Luigi Almasio; C Ciaccio; Marcello Capra; Michele Rizzo; Roberto Malizia; Aurelio Maggio; Carmelo Fabiano; Franco Barbaria; Antonio Craxì
Long-term efficacy of alpha-interferon in beta-thalassemics with chronic hepatitis C.
Blood 1997;90(6):2207-12.
1997: Calogero Cammà; M Giunta; Piero Luigi Almasio; Vito Di Marco; Antonio Craxì
Moving towards the optimal treatment of chronic hepatitis C.
Italian journal of gastroenterology and hepatology 1997;29(1):69-74.
1997: evangelista sagnelli; Tommaso Stroffolini; Antonio Ascione; Maria Chiaramonte; Antonio Craxì; G Giusti; Felice Piccinino
Decrease in HDV endemicity in Italy.
Journal of hepatology 1997;26(1):20-4.
1997: Vito Di Marco; Oreste Lo Iacono; Calogero Cammà; Piero Luigi Almasio; A Vaccaro; P Fuschi; M Giunta; Carmelo Fabiano; Luigi Pagliaro; Antonio Craxì
A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C.
Journal of medical virology 1997;51(1):17-24.
1996: Antonio Craxì; Vito Di Marco; Calogero Cammà; Piero Luigi Almasio; S Magrin
Duration of HCV infection as a predictor of nonresponse to interferon.
Digestive diseases and sciences 1996;41(12 Suppl):86S-92S.
1996: G Provenzano; Piero Luigi Almasio; Carmelo Fabiano; S Magrin; G Pinzello; A Vaccaro; Antonio Craxì
Interferon and steroid treatment in patients with chronic hepatitis C and antinuclear or anti-liver-kidney microsomal antibodies.
The Italian journal of gastroenterology 1996;28(7):377-80.
1996: Antonio Craxì; Piero Luigi Almasio; S Schalm
Evaluation of efficacy of antiviral therapy for chronic hepatitis C: a EUROHEP Consensus Report on response criteria.
Journal of viral hepatitis 1996;3(5):273-6.
1996: Calogero Cammà; Piero Luigi Almasio; Antonio Craxì
Interferon as treatment for acute hepatitis C. A meta-analysis.
Digestive diseases and sciences 1996;41(6):1248-55.
1996: Antonio Craxì; Vito Di Marco; Oreste Lo Iacono; Piero Luigi Almasio; R Bruno; Calogero Cammà; R Volpes; Luigi Pagliaro
Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months.
Journal of hepatology 1996;24(5):539-46.
1996: Antonio Craxì; Piero Luigi Almasio
Diagnostic approach to liver enzyme elevation.
Journal of hepatology 1996;25 Suppl 1():47-51.
1996: Antonio Craxì; Vito Di Marco; Piero Luigi Almasio
Hepatic hepatitis C virus RNA in chronic hepatitis C.
Annals of internal medicine 1996;124(1 Pt 1):72.
1995: Antonio Craxì; S Magrin; Carmelo Fabiano; C Linea; Piero Luigi Almasio
Host and viral features in chronic HCV infection: relevance to interferon responsiveness.
Research in virology 1995;146(4):273-8.
1994: Antonio Craxì; M Valenza; Carmelo Fabiano; S Magrin; G Fiorentino; O Diquattro; Luigi Pagliaro
Third-generation hepatitis C virus tests in asymptomatic anti-HCV-positive blood donors.
Journal of hepatology 1994;21(5):730-4.
1993: F Tinè; Alessandro Liberati; Antonio Craxì; Piero Luigi Almasio; Luigi Pagliaro
Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature.
Journal of hepatology 1993;18(2):154-62.
1993: G Provenzano; O Diquattro; Antonio Craxì; Piero Luigi Almasio; G Pinzello; L Marino; G Fiorentino; F Rinaldi; Luigi Pagliaro
Immunoblotting as a confirmatory test for antimitochondrial antibodies in primary biliary cirrhosis.
Gut 1993;34(4):544-8.
1993: Antonio Craxì; Vito Di Marco; Oreste Lo Iacono; Piero Luigi Almasio; Carmelo Fabiano; G Fiorentino; L Marino; S Magrin; G Pinzello; S Sammarco
The natural history of chronic HDV infection.
Progress in clinical and biological research 1993;382():301-10.
1992: S Magrin; Antonio Craxì; Carmelo Fabiano; G Fiorentino; L Marino; Piero Luigi Almasio; G B Pinzello; U Palazzo; M Vitale; Aurelio Maggio
Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis.
Journal of medical virology 1992;38(3):200-6.
1992: Piero Luigi Almasio; G Provenzano; M Scimemi; G Cascio; Antonio Craxì; Luigi Pagliaro
Hepatitis C virus and Sjögren's syndrome.
Lancet 1992;339(8799):989-90.
1992: S Magrin; G Pinzello; Antonio Craxì; Piero Luigi Almasio; Luigi Pagliaro
Anti-HCV, anti-GOR, and autoimmunity.
Lancet 1992;339(8797):871.
1992: R G Simonetti; Calogero Cammà; F Fiorello; Mario Cottone; Maria Rapicetta; L Marino; G Fiorentino; Antonio Craxì; Anna Rita Ciccaglione; Roberto Giuseppetti
Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study.
Annals of internal medicine 1992;116(2):97-102.
1992: Antonio Craxì; Vito Di Marco; R Bruno; Carmelo Fabiano
Hepatitis delta superinfection during alpha-interferon treatment for hepatitis B.
The Italian journal of gastroenterology 1992;24(1):19-20; discussion 20-1.
1991: Calogero Cammà; G Garofalo; Piero Luigi Almasio; F Tinè; Antonio Craxì; U Palazzo; G Pinzello; F Fiorello; P M Angelo; Luigi Pagliaro
A performance evaluation of the expert system 'Jaundice' in comparison with that of three hepatologists.
Journal of hepatology 1991;13(3):279-85.
1991: Antonio Craxì; F Tinè; M Vinci; Piero Luigi Almasio; Calogero Cammà; G Garofalo; Luigi Pagliaro
Transmission of hepatitis B and hepatitis delta viruses in the households of chronic hepatitis B surface antigen carriers: a regression analysis of indicators of risk.
American journal of epidemiology 1991;134(6):641-50.
1991: F Tinè; S Magrin; Antonio Craxì; Luigi Pagliaro
Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials.
Journal of hepatology 1991;13(2):192-9.
1991: S Magrin; Antonio Craxì; G Fiorentino; Carmelo Fabiano; G Provenzano; G B Pinzello; U Palazzo; Piero Luigi Almasio; Luigi Pagliaro
Is autoimmune chronic active hepatitis a HCV-related disease?
Journal of hepatology 1991;13(1):56-60.
1991: Antonio Craxì; G Fiorentino; Vito Di Marco; L Marino; S Magrin; C Fabriano; Luigi Pagliaro
Second generation tests in diagnosis of chronic hepatitis C.
Lancet 1991;337(8753):1354.
1991: G Provenzano; L Marino; Antonio Craxì
Features of autoimmunity in cryptogenic chronic hepatitis.
Allergologia et immunopathologia 1991;19(3):119-22.
1991: Antonio Craxì; Vito Di Marco; R Volpes; S Marra; M Rizzetto; F Rosina; Cristiana Barbera; F Bortolotti; Carlo Crivellaro; C Iannuzzi
Treatment with recombinant alpha 2b-interferon of chronic HDV hepatitis in children.
Progress in clinical and biological research 1991;364():399-404.
1991: Paolo Colombo; F Di Blasi; S Magrin; Carmelo Fabiano; Vito Di Marco; L D'Amelio; F Lojacono; Giovanni Spinelli; Antonio Craxì
Smouldering hepatitis B virus replication in patients with chronic liver disease and hepatitis delta virus superinfection.
Journal of hepatology 1991;12(1):64-9.
1991: S Margin; Antonio Craxì; Carmelo Fabiano; G Fiorentino; Piero Luigi Almasio; Vito Di Marco; Oreste Lo Iacono; R Bruno; G B Pinzello; U Palazzo
Hepatitis C virus replication in chronic liver disease.
Journal of hepatology 1991;13 Suppl 4():S40-1.
1989: S Magrin; Antonio Craxì; C Carini; Paolo Colombo; F di Blasi; Giovanni Spinelli; C Fratazzi; M C Messina; G Antonelli; C Ausiello
Interleukin-2, interleukin-2 receptor and gamma-interferon synthesis by peripheral blood mononuclear cells in chronic hepatitis delta virus infection.
Journal of hepatology 1989;8(3):358-66.
1989: Antonio Craxì; M Vinci; Piero Luigi Almasio; Luigi Pagliaro
Hepatitis B vaccination of relatives of hepatitis B virus DNA positive carriers: an experience with plasma-derived vaccine.
European journal of epidemiology 1989;5(1):65-9.
1989: Antonio Craxì; Vito Di Marco; R Volpes; R Bruno; U Palazzo; Aurelio Maggio
Alpha-interferon and post-transfusion NANB hepatitis.
Lancet 1989;1(8634):391-2.
1988: Antonio Craxì; L Marino; E Aragona; C Patti
IgM anti-HBc in acute and chronic hepatitis B virus (HBV) infection: diagnostic value and correlation with viral replication and disease activity.
Bollettino dell'Istituto sieroterapico milanese 1988;67(4):275-82.
1987: Antonio Craxì; Vito Di Marco; S Magrin; I Scalisi; R Vassallo; M Vinci; G Genova; G D'Amico; S Maisano; F Politi
The natural history of chronic type B hepatitis in southern Italy: effect of HBV replication and of HDV infection.
Progress in clinical and biological research 1987;234():153-65.
1987: Antonio Craxì; Paolo Colombo; G D'Amico; F Di Blasi; Vito Di Marco; S Magrin; S Maisano; F Politi; I Scalisi; Giovanni Spinelli
Hepatitis B infection and liver cirrhosis: a reappraisal from the Mediterranean area.
Annali dell'Istituto superiore di sanità 1987;24(2):257-65.
1986: S Magrin; Antonio Craxì; M Vinci; J Greco; GIUSEPPE MAGGIORE; J Scotto; Luigi Pagliaro
Assessment of HBV replicative status by receptors for polymerized human albumin.
Hepato-gastroenterology 1986;33(1):6-8.
1985: Antonio Craxì; S Magrin; J Greco; M Vinci; F Tinè; G Raimondo; G Longo; Luigi Pagliaro
Polyalbumin receptors, hepatitis B surface antigen (HBsAg), and HBsAg/IgM complexes in HBsAg positive patients with and without delta superinfection.
Journal of medical virology 1985;15(4):383-8.
1985: GIUSEPPE MAGGIORE; M Hadchouel; F Sessa; M Vinci; Antonio Craxì; M D Marzani; C De Giacomo; D Alagille
A retrospective study of the role of delta agent infection in children with HBsAg-positive chronic hepatitis.
Hepatology (Baltimore, Md.) 1985;5(1):7-9.
1984: Antonio Craxì; G Raimondo; G Longo; G Giannuoli; R De Pasquale; M Caltagirone; S Patti; G Squadrito; Luigi Pagliaro
Delta agent infection in acute hepatitis and chronic HBsAg carriers with and without liver disease.
Gut 1984;25(11):1288-90.
1983: G Pinzello; R G Simonetti; Antonio Craxì; S Di Piazza; C Spanò; Luigi Pagliaro
Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic cirrhotic patients.
Hepatology (Baltimore, Md.) 1983;3(4):545-9.
1983: Antonio Craxì; G Raimondo; G Giannuoli; G Longo; M Caltagirone; M Aragona; G Squadrito; Luigi Pagliaro
Delta agent and hepatocellular carcinoma.
Progress in clinical and biological research 1983;143():231-4.
1983: Luigi Pagliaro; F Rinaldi; Antonio Craxì; S Di Piazza; G Filippazzo; G Gatto; G Genova; S Magrin; Alberto Maringhini; S Orsini; U Palazzo; M Spinello; M Vinci
Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial.
Digestive diseases and sciences 1983;28(1):39-43.